Findings

What do systematic reviews say?

12 questions · 12 findings · 2 reviews · Cystic Fibrosis and Genetic Disorders · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 58.3%GRADE not reported 0 · 0%Very low 1 · 8.3%Low 4 · 33.3%Moderate 0 · 0%High 0 · 0%

Morning vs evening inhalation of dornase alfa

Adverse effects · adults and children with cystic fibrosis

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

Morning showed no clear difference in FEV1 (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

Morning showed no clear difference in FVC (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

Measures of QoL and symptom scores · adults and children with cystic fibrosis

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
25 participants
Low

Morning vs evening inhalation of dornase alfa

FEF25-75 · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

QoL · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Androgen normalisation · people with CAH

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Prevention of adrenal crisis · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Presence of osteopenia · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Presence of testicular or ovarian adrenal rest tumours · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Subfertility · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

Final adult height · people with CAH

The review found no eligible studies for this question.

1 finding from 1 review

Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found